In summary, the effects of tirzepatide with its dual mechanism of action and the upcoming triple agonists (GLP-1/GIP/glucagon receptor triagonist) with greater outcomes on weight loss have the potential to outperform the known effects of single GLP-1Ras and become an alluring treatment option for MASLD or MASH, especially for patients with coexisting diabetes mellitus or obesity. Here, GLP1R is linked to diabetes mellitus.